Home / Resources (page 89)



AACE Algorithm

The suggested hierarchy of usage (AACE Algorithm) for a patient on metformin who has not reached goal according to the new 2018 AACE goal in 3 months is: A. GLP-1RA, SGLT-2i, TZD, Basal Insulin, DPP4i B. SGLT-2i, GLP-1RA, TZD. DPP4i, Basal Insulin C. GLP-IRA, DPP4i, GLP-1RA, Bromocriptine QR D. SGLT-2i, TZD, GLP-1RA, Colesevelem E. SGLT-21, GLP-1RA, Basal Insulin, Colesevelem Follow the link for the answer.

Read More »

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #112: Diabetes and Sleep Apnea Part 2

OSA epidemiology and risk factors: The prevalence of OSA varies considerably between studies, mainly due to differences in the population studied, study designs, and the method and criteria used to diagnose OSA. A prevalence of 4% in men and 2% in women has traditionally been quoted in many populations. The prevalence from three well-conducted studies with similar design from Wisconsin, Pennsylvania, and Spain showed an OSA prevalence of 17–26% in men and 9–28% in women and a prevalence of 9–14% and 2–7% for men and women with moderate to severe OSA. These studies used a two-stage sampling design which allows some degree of estimate of the “self-selection” bias which is usually a significant problem in OSA studies.

Read More »

Point-Counterpoint, Part 1: How to Overcome the Complexities of Treatment Decisions for Your Patients with Type 2 Diabetes

In the last four issues, we discussed a new software that can go through over 6 million possible treatments using anywhere from 1 to 5 drugs for an effective treatment for type 2 diabetes. Along with determining the best treatment for the patient, it includes the ability to put in what the patient can afford in their budget. Dr. John Interlandi, one of our readers, has submitted a counterpoint to using this software to decide the best treatment options. In Part 1, Dr. Interlandi shares his concerns about the use of AI in medical decision making. 

Read More »